Intralesional Cyclosporine for Alopecia Areata

This study is investigating a new way to treat Alopecia Areata (a condition where your immune system attacks hair follicles, causing hair loss). Researchers are testing if injecting Cyclosporine directly into the affected scalp areas can help hair regrow. Cyclosporine is a medication that has been used for other skin conditions like psoriasis. You may be able to join if you are between 18 and 65 years old, have had Alopecia Areata on your scalp for over three months, and meet specific hair loss criteria. The study will measure hair regrowth using a special score (SALT Score), patient reports, and photographs over 12 weeks. The current status of this study is unclear, and it plans to enroll 12 participants.

Study design: This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 12 participants.
What's involved: Not specified in the trial record.
Compensation: Not stated in the trial record.
Follow-up: Hair regrowth will be measured at week 12, indicating a follow-up period of at least 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Intralesional Cyclosporine for Alopecia Areata

Active, Not Recruiting

EARLY_PHASE1Ages 18–65InterventionalTreatment

University of California, Davis

~2 participants

Updated 2026-08-06 on ClinicalTrials.gov

What's tested:CycloSPORINE Injectable ProductSaline Solution

At a glance

Recruiting sites

0 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

Hair Regrowth: SALT Score

Measured over Screening to Week 12

+2 more outcomes measured

Conditions

Alopecia Areata

Where it's being run

1 sites across 1 states

California1

Study leadership

Oma Agbai, MD · PRINCIPAL_INVESTIGATOR · UC Davis Health Department of Dermatology

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

Age between 18 and 65 at screening visit.

Diagnosis of alopecia areata by a board-certified dermatologist at screening visit.

Current alopecia areata episode involving the scalp of more than 3 months' duration prior to baseline visit.

SALT Score between 10 and 50 at baseline visit.

Stable disease based on subject history over the past 1 month.

Agree not to use any alopecia areata treatments during the study, including, but not limited to: systemic therapies (eg, methotrexate, cyclosporine, corticosteroids, JAK inhibitors) and biologics (eg, monoclonal antibodies), intralesional corticosteroid injections, topical therapies, and phototherapy

Exclusion

Currently experiencing other forms of alopecia. Including but not limited to: androgenetic alopecia, telogen effluvium, or any other concomitant conditions (eg, tinea capitis, psoriasis, lupus erythematosus, or secondary syphilis) that could interfere with evaluation of alopecia areata

Previous treatment with cyclosporine

Other autoimmune diseases

Pregnancy or lactation

Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute an unacceptable risk when taking study drug or interfere with the interpretation of data. These may include, but are not limited to, patients with untreated hypertension, patients with known renal disease with decreased GFR, and known infection.

Adults unable to consent

Prisoners

Currently using drugs that are well-substantiated to interact with cyclosporine, including the following: ciprofloxacin, gentamicin, tobramycin, trimethoprim with sulfamethaxazole, vancomycin, melphalan, amphotericin B, ketoconazole, azapropazon, colchicine, diclofenac, naproxen, sulindac, cimetidine, ranitidine, tacrolimus, fibric acid derivatives (e.g. bezafibrate, fenofibrate), and methotrexate.

What this trial measures

Hair Regrowth: SALT ScoreScreening to Week 12
Using the Severity of Alopecia Tool (SALT), study team will track and monitor the percentage of scalp hair loss throughout participant's duration in the trial.
Hair Regrowth: PRO for scalp hair assessmentWeek 0 and Week 12
PRO for scalp hair assessment will be a questionnaire given to participants where they will elevate their hair loss on a scale of 0-4.
Hair Regrowth: Standardized photographsWeek 0 to Week 12
Standardized photographs of participant's scalps will be taken throughout the course of the study to visual monitor outcomes. There will be a minimum of 5 photographs taken: one of each of the 4 planes of scalp and 1 frontal view of face and scalp. These photographs will be compared to one another through the study to assess the hair regrowth that occurred following the cyclosporine injections.

Trialytics